Diabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AmideBio

AmideBio LLC, a privately held biopharmaceutical company, announced today that Dr. Pawel Fludzinski has joined the Company as its new Chief Executive Officer. With his extensive background in the development of drugs targeting diabetes at Eli Lilly & Co, Dr. Fludzinski was selected as the ideal candidate to lead AmideBio’s development of its pipeline of drug candidates targeting metabolic diseases. Read the full press release.